ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Memorial Sloan Kettering Cancer Center at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Memorial Sloan Kettering Cancer Center takes part in 56 sessions at ESMO 2026 in Madrid. Its program spans treatment across cancer types, with a focus on precision oncology and immunotherapy. Topics include using circulating tumor DNA to track remission and resistance, and AI-based integration of real-world data to predict outcomes.
| Organization | ESMO 2026 Attendance |
|---|---|
Memorial Sloan Kettering Cancer Center New York, NY | |
Cancer treatment and research centre in New York City, New York. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Real-world patterns of care and outcomes of patients with metastatic clear cell sarcoma (CCS) and gastrointestinal neuroectodermal tumor (GNET) Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30–13:45 Chair Fri Oct 23 13:30–15:00 Abstract Fri Oct 23 13:35–13:40 1210RO - Safety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT) Genitourinary cancersGastrointestinal cancers Abstract Fri Oct 23 14:32–14:42 Poster Fri Oct 23 15:15–16:00 A chromosomal instability signature identifies patients with BRCA wild-type cancers who benefit from PARP inhibitors across four HRD-associated cancer types Gastrointestinal cancersGynaecological cancersBreast cancerBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Cell free DNA concordance with tissue sequencing and actionability across clinical states of prostate cancer Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Circulating tumor DNA as a marker of durable remission after non-operative management of mismatch repair deficient rectal cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Genetic dementia risk and androgen receptor (AR) therapy-associated cognitive effects (ARTACE) results from AFT-47, a randomized comparison of darolutamide (DAR) and enzalutamide (ENZ) Genitourinary cancersNursing & supportive care Poster Fri Oct 23 15:15–16:00 Genomic characterization and prognostic impact of the TP53-Y220C mutation across solid tumors in real-world data Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Talk Fri Oct 23 15:15–15:35 Poster Fri Oct 23 15:15–16:00 Targeting DNA damage repair via exportin-1 inhibition to delay resistance to targeted therapy in RET-fusion lung cancer Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers Talk Fri Oct 23 16:15–17:15 Talk Fri Oct 23 16:35–16:55 T-cell therapy in sarcoma: A hopeful future or unreachable reality? Sarcoma, CNS, head & neck and rare cancers Satellite Fri Oct 23 19:00–19:25 Chair Sat Oct 24 08:30–10:00 Talk Sat Oct 24 09:00–09:15 Beyond immune-checkpoint inhibition Gastrointestinal cancers Abstract Sat Oct 24 09:14–09:19 Talk Sat Oct 24 09:30–09:50 Survival tactics: Adaptation mechanisms in metastatic tumors Biomarkers & precision oncology Abstract Sat Oct 24 09:32–09:44 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Keynote Sat Oct 24 12:20–12:45 Chair Sat Oct 24 14:45–16:15 Proffered paper: Gynaecological cancers Gynaecological cancers Chair Sat Oct 24 14:45–16:15 Rapid oral: Gastrointestinal tumours, lower digestive Gastrointestinal cancers Abstract Sat Oct 24 14:55–15:05 3715O - A phase 1/2 trial of zolucatetide, a first-in-class direct β-catenin:TCF inhibitor: Updated safety and efficacy in patients with desmoid tumors Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 15:00–15:15 Invited Discussant 787RO, 788RO and 789RO Gastrointestinal cancers Abstract Sat Oct 24 15:15–15:27 Invited Discussant 1239O, LBA36 and LBA37 Gynaecological cancers Talk Sun Oct 25 09:10–09:30 Chair Sun Oct 25 10:15–11:45 Talk Sun Oct 25 10:15–10:30 Chair Sun Oct 25 10:15–11:45 Proffered paper: Gastrointestinal tumours, lower digestive Gastrointestinal cancers Talk Sun Oct 25 10:15–10:30 Abstract Sun Oct 25 11:00–11:10 Poster Sun Oct 25 12:00–12:45 AI-driven drug discovery for gastroesophageal adenocarcinoma Gastrointestinal cancers Poster Sun Oct 25 12:00–12:45 AlphaMissense (AM) reclassifies DNA damage repair (DDR) variants of unknown significance and identifies a subset associated with survival in metastatic urothelial carcinoma (mUC) Genitourinary cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Pathogenic ATM loss defines pancreatic cancer (PC) with better prognosis, reduced liver tropism and distinct KRAS-tumor microenvironment (TME) biology Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Chair Sun Oct 25 12:00–12:50 What oncologists should know about non-pharmaceutical interventions Nursing & supportive care Talk Sun Oct 25 12:30–12:45 Integrative oncology: What is the evidence? Nursing & supportive care Chair Sun Oct 25 14:45–16:00 LARC: The essential role of multidisciplinary management of locally advanced rectal cancer Gastrointestinal cancers Talk Sun Oct 25 14:45–15:05 Locally advanced gastric and gastroesophageal cancer: Perioperative therapy Gastrointestinal cancers Chair Sun Oct 25 14:45–16:25 Chair Sun Oct 25 14:45–16:15 State-of-the-art treatment for non metastatic upper GI cancers Gastrointestinal cancers Talk Sun Oct 25 15:30–15:50 Tailoring post TNT strategies based on tumour response Gastrointestinal cancers Abstract Sun Oct 25 15:35–15:45 Chair Sun Oct 25 16:30–17:15 Frontline treatment for leiomyosarcoma: What level of evidence is required for clinical implementation? Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 17:54–18:06 Invited Discussant LBA8 Lung & thoracic cancersGastrointestinal cancers Chair Mon Oct 26 08:30–10:00 Rapid oral: Sarcoma Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 08:40–08:45 Abstract Mon Oct 26 09:34–09:39 3725RO - Lifileucel in patients with undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLS) Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 09:39–09:51 Invited Discussant 3723RO, 3724RO and 3725RO Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 10:15–11:45 Rapid oral 2: Breast cancer, advanced stage Breast cancer Talk Mon Oct 26 11:15–11:35 Immunotherapy in pancreatic cancer: Overcoming barriers to Success Gastrointestinal cancers Abstract Mon Oct 26 11:32–11:42 Invited Discussant 1769RO, 1770RO and 4449RO Breast cancer Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 A pooled analysis of zongertinib treatment in HER2-overexpressed/amplified NSCLC Lung & thoracic cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Clinical outcomes and recurrence patterns in early-stage fusion-positive NSCLC treated with initial surgery or SBRT: A retrospective institutional analysis Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Endometrial cancer (EC): Patients (Pts) raise their voices Gynaecological cancersNursing & supportive care Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Molecular profiling of primary tumors and distant metastases in malignant mesotheliomas Lung & thoracic cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Neoadjuvant cemiplimab and cetuximab in resectable oral cavity squamous cell carcinoma (OCSCC) Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Talk Mon Oct 26 12:00–12:15 Somatic vs germline: Avoiding the most common mistakes Biomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Sub-analysis of a phase 2 study investigating amrecibart and cenvacibart for the prevention of contact-mediated venous thromboembolism (VTE) in participants with active cancer undergoing peripherally inserted central catheter (PICC) placement (ROXI-CATH) Haematological malignanciesNursing & supportive care Chair Mon Oct 26 12:00–12:50 What oncologists should know about interpreting tumour sequencing Biomarkers & precision oncology Abstract Mon Oct 26 14:45–14:55 Talk Mon Oct 26 14:50–15:10 Diagnostic and prognostic assessment Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 15:10–15:35 Clinical trials and regulatory landscape in tumour-agnostic oncology Biomarkers & precision oncology |
Find decision makers at Memorial Sloan Kettering Cancer Center
Tell us what you sell and we’ll find the people at Memorial Sloan Kettering Cancer Center most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction